TU LIN, M.D.; JOSEPH R. TUCCI, M.D., F.A.C.P.
Seven tests of growth-hormone release were evaluated in 31 hospitalized nonobese persons without evidence of endocrine disease. Plasma growth-hormone levels were measured before and after administration of insulin, 0.1 unit/kg body weight intravenously; glucagon, 1 mg intramuscularly; levodopa, 500 mg by mouth; metyrapone, 750 mg by mouth; α 1-24-ACTH (cosyntropin), 0.25 mg intravenously; and 1 to 2 hours after the onset of nocturnal sleep, and after 15 minutes of vigorous stair climbing. Insulin uniformly stimulated growth-hormone release in all 19 persons tested, whereas 21 of 24 (87%) responded to levodopa and 17 of 21 (81%) to glucagon. ACTH stimulated growth-hormone release in only 7 of 12 persons, whereas metyrapone had no effect. A growth-hormone response to sleep was found in only 2 of 11, whereas exercise stimulated growth-hormone release in 4 of 10. Although the highest growth-hormone levels were associated with insulin hypoglycemia, these were not significantly different from levels after administration of levodopa or glucagon (P > 0.05). These data suggest that levodopa is a reasonably effective alternative to insulin hypoglycemia as a test of growth-hormone release. Its advantages are that it is given orally, and there are minor side effects. The efficacy of glucagon approaches that of levodopa.
LIN T, TUCCI JR. Provocative Tests of Growth-Hormone Release: A Comparison of Results with Seven Stimuli. Ann Intern Med. ;80:464–469. doi: 10.7326/0003-4819-80-4-464
Download citation file:
Published: Ann Intern Med. 1974;80(4):464-469.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use